Phase 1b Study of Epcoritamab Combined With Ibrutinib for Treating Relapsed or Refractory Central Nervous System Lymphoma

What this Trial Is About

Researchers are evaluating whether combining epcoritamab and ibrutinib is a safe treatment option with few or mild side effects for people with relapsed or refractory primary or secondary central nervous system lymphoma PCNSL or SCNSL. This phase 1 trial focuses on determining the safety and tolerability of this combination therapy in these lymphoma patients. Participants will receive epcoritamab as a subcutaneous injection at the study site clinic and self-administer oral ibrutinib daily at approximately the same time each day. The study includes several cohorts of patients with relapsed or refractory PCNSL. The treatment duration and dose escalation details are managed according to the trial protocol. Throughout the study, participants will undergo regular assessments including MRI or CT scans to monitor disease status and safety. Researchers will track dose-limiting toxicities over an eight-week period as the main outcome. Participants must complete required laboratory tests, physical exams, and pregnancy tests if applicable, and will be monitored for adverse effects and overall health during treatment. The study is expected to continue until August 2028.

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)